Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Harvard Business School
Fish and Richardson
Colorcon
McKinsey
Covington
Argus Health
Healthtrust

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMNIPAQUE 240

« Back to Dashboard

Clinical Trials for Omnipaque 240

Trial ID Title Status Sponsor Phase Summary
NCT00478556 Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT Completed GE Healthcare Phase 4 Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00478556 Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT Completed University of Alabama at Birmingham Phase 4 Patients who are scheduled by their health care provider for routine computed tomography (CT) scan will be asked to participate in this study. The primary purpose is to determine if there is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference in bowel opacification for the two agents.
NCT00587132 Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma Terminated ChiRhoClin, Inc. Phase 1/Phase 2 The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
NCT00587132 Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma Terminated Mayo Clinic Phase 1/Phase 2 The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
NCT00857792 Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging Completed Astellas Pharma Inc N/A The investigators goals are: 1. to develop software for quantitative volumetric analysis of myocardial perfusion from MDCT images 2. to test its ability to accurately determine the presence, location, extend and severity of perfusion abnormalities in agreement with conventional diagnostic techniques (ICA and MPI) in patients with normal and abnormal coronary arteries and/or perfusion patterns 3. to test this approach in patients undergoing vasodilator stress tests with MDCT imaging in combination with the new vasodilator stress agent Regadenoson.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Omnipaque 240

Condition Name

Condition Name for Omnipaque 240
Intervention Trials
Batten Disease 1
HIV 1
Sepsis 1
Aging 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Omnipaque 240
Intervention Trials
Coronary Artery Disease 2
Myocardial Ischemia 2
Tuberculosis 1
Neuronal Ceroid-Lipofuscinoses 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Omnipaque 240

Trials by Country

Trials by Country for Omnipaque 240
Location Trials
United States 8
Colombia 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Omnipaque 240
Location Trials
Minnesota 2
Pennsylvania 1
Ohio 1
Florida 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Omnipaque 240

Clinical Trial Phase

Clinical Trial Phase for Omnipaque 240
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 1/Phase 2 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Omnipaque 240
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Omnipaque 240

Sponsor Name

Sponsor Name for Omnipaque 240
Sponsor Trials
GE Healthcare 2
Duke Clinical Research Institute 1
ViiV Healthcare 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Omnipaque 240
Sponsor Trials
Other 13
Industry 10
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Harvard Business School
Accenture
Chubb
Merck
Federal Trade Commission
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.